---
schema_version: "secwatch.filing_event.v1"
accession: "0000064803-23-000046"
form_type: "8-K"
ticker: "CVS"
cik: "0000064803"
company_name: "CVS HEALTH Corp"
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T03:30:51.580210+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CVS Health Q3 revenue $89.8B (+10.6%), GAAP EPS $1.75, Adj EPS $2.21, FY GAAP EPS guidance revised to $6.37-$6.61

## Summary
- Total revenues $89.8B, up 10.6% YoY; GAAP diluted EPS $1.75 vs loss of $2.59 prior year.
- Adjusted EPS $2.21 vs $2.17 prior year; YTD cash flow from operations $16.1B.
- FY GAAP EPS guidance revised to $6.37-$6.61 from $6.53-$6.75; adjusted EPS guidance confirmed at $8.50-$8.70.
- Launched Cordavis to commercialize biosimilars; Aetna's 2024 Medicare offerings expanded.
- Appointed Scott Kirby (United Airlines CEO) and Michael Mahoney (Boston Scientific CEO) to board.

## SEC filing metadata
- accession: 0000064803-23-000046
- form_type: 8-K
- ticker: CVS
- cik: 0000064803
- company_name: CVS HEALTH Corp
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/64803/000006480323000046/0000064803-23-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/64803/000006480323000046/cvs-20231101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000064803-23-000046
- JSON: https://secwatch.observer/filing/0000064803-23-000046.json
- Plain text: https://secwatch.observer/filing/0000064803-23-000046.txt

## Key facts
- Earnings Releases
  CVS HEALTH Corp reported three months ended September 30, 2023 results: revenue $89.8 billion, EPS GAAP diluted EPS of $1.75 and Adjusted EPS of $2.21. Guidance reaffirmed.
  - Period: three months ended September 30, 2023
  - Revenue: $89.8 billion
  - EPS: GAAP diluted EPS of $1.75 and Adjusted EPS of $2.21
  - Guidance: reaffirmed
  - Result: reported results
  source text: (NYSE: CVS) today announced operating results for the three months ended September 30, 2023. Third quarter highlights Key financial data • Total revenues increased to $89.8 billion, up 10.6% compared to prior year • GAAP diluted EPS of $1.75 and Adjusted EPS of $2.21 Year-to-date highlights • Total revenues increased to $264.0 billion, up 10.6% compared to
  evidence_url: https://www.sec.gov/Archives/edgar/data/64803/000006480323000046/0000064803-23-000046-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.